EDGC, a bio big data company, announced that the company held a public briefing session for shareholders and institutional investors on June 26, 2019, at the Korea Exchange. 

In this large-scale public session, EDGC officials reported the recent status of domestic and international businesses and the number of major genome analysis services. In Q&A session with participants, EDGC officials explained the company’s strong point as non-invasive diagnostic tests using cfDNA as well as liquid biopsy, and pointed out that development of analytical algorithms and various genome analysis services using genome data is the company’s key technology. The company officials evaluated the session as a good opportunity for interactive communication with shareholders and institutional investors.

Shin Sang-cheol, co-CEO of EDGC, said, “In this public briefing, we shared our vision to maximize the company’s sales, including turning our headquarters into a global R&D and marketing organization, and operating our overseas partners as joint venture and as sales organization by means of technology transfer. The convertible bonds issued recently are to realize tailored and precision medicine based on R&D projects that aim to build precise genome analysis and bio big data. We will maximize shareholder value and build trust with our investors by leading growth and the latest trends of the global genomics industry as well as of countries such as Thailand, Singapore, U.S., India, and Philippines that we already are making business with. 

EDGC officials also introduced the company’s core services such as NICE(NIPT service), bebegene(newborn screening service), gene2me Plus(cancer and common disease risk prediction service), MyEyeGene(eye disease risk prediction service), telomere length measurement service, EDGC S-CAN(liquid biopsy service), and DNA App in the public briefing.